Xencor Licenses Fc Antibody Engineering IP to Merck MONROVIA, Calif., July 2, 2013 – Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the United States and Canada, access to one of Xencor's Fc

Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia MONROVIA, Calif., April 26, 2013 – Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic

Xencor Licenses Xtend ™ Therapeutic Protein Half-life Extension Technology to CSL MONROVIA, Calif., and MELBOURNE, Australia, April 16, 2013—Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend™

Xencor Initiates Phase 1b/2a Trial of XmAbR5871 for Autoimmune Disease MONROVIA, Calif., February 13, 2013—Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis.

MONROVIA, Calif., January 17, 2013—Xencor, Inc. today announced it has received a milestone payment from Janssen Research & Development, LLC (Janssen R&D) resulting from the exercised option for the use of Xencor's Xtend™ half-life extension technology in a therapeutic antibody.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical

Martinsried/Munich, Germany, and Monrovia, Calif., USA, May 22, 2012—MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

SEVENTH ANTIBODY DEVELOPED WITH XENCOR'S XmAb TECHNOLOGY MOVES INTO HUMAN TRIALS

Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement MONROVIA, Calif., April 4, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.

Antibodies engineered with Xencor's proprietary Xtend&#8482 technology for increasing antibody half-life